drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR T)
drug_description
Autologous T cells genetically engineered to express a HER2 (ERBB2)-specific chimeric antigen receptor; upon binding HER2 on tumor cells, they activate cytotoxic T-cell responses leading to tumor cell killing.
nci_thesaurus_concept_id
C201497
nci_thesaurus_definition
A preparation of T-lymphocytes that express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a HER2-specific chimeric antigen receptor. Upon binding HER2 (ERBB2) on tumor cells, the CAR transduces activation signals (CD3ΞΆ with costimulatory domains), driving T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytolytic killing of HER2-expressing cancer cells.
drug_name
Anti-HER2 CAR-T cells
nct_id_drug_ref
NCT06101082